For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

27th Jul 21

Pharmaxis Quarterly Shareholder Update and Investor Presentation

Investor Briefing

Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on 28 July 2021.

Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 1.00pm AET on Thursday 29 July 2021.

The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.

To register and receive your conference link please click here.

To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to:

Read full media release - pdf
1st Jul 21

Pharmaxis Sells Bronchitol and Aridol Australian Distribution Rights for A$2m

  • Pharmaxis sells Australian distribution rights for Bronchitol®and Aridol® in Australia, New Zealand and several Asian territories to BTC Health effective July 1st, 2021
  • $2m distributor appointment fee to be paid to Pharmaxis
  • Streamlining  mannitol respiratory business in line with strategy
Read full media release - pdf
29th Jun 21

Pharmaxis Announces First Results in Bone Marrow Cancer Trial

First Dose Level in PXS-5505 Myelofibrosis Study Showing Strong Inhibition of Target Enzymes LOX and LOKL2 in Patients

Dosing Commenced in Second Cohort Following Successful Recruitment

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced results of data analysis from the first of three stages in its phase 1c clinical trial (MF-101) studying a potential new treatment for the bone marrow cancer myelofibrosis. In addition to the good tolerability and consistent pharmacokinetic properties previously announced, the inhibition of two target enzymes, LOX and LOXL2, were assessed with Pharmaxis proprietary assays and found to be highly statistically significant.

Read full media release - pdf